Search results
Results from the WOW.Com Content Network
An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. They may be used for severe cases of gastroenteritis, especially if the patient is dehydrated. [1] [2]
العربية; Беларуская (тарашкевіца) Čeština; Deutsch; Ελληνικά; Español; Esperanto; Euskara; فارسی; Français; 한국어
Aprepitant is classified as an NK 1 antagonist because it blocks signals given off by NK 1 receptors.This, therefore, decreases the likelihood of vomiting in patients. NK 1 is a G protein-coupled receptor located in the central and peripheral nervous system.
Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, [6] administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States, [7] and in the European Union in January 2008. [5]
Cyclizine was quickly clinically found as a potent and long-acting antiemetic. The company named the substance – or more precisely cyclizine's hydrochloride form which it usually appears in – "marezine hydrochloride" and started to sell it in the United States under trade name Marezine. Selling was begun in France under trade name Marzine ...
T he Trump Administration took down parts of some government websites as well as removed several health data sets on Friday, raising alarm among health care providers and researchers who use ...
"The Use of Medicines in the United States". IMS Institute for Healthcare Informatics. The Use of Medicines in the United States. June 2012. p. 40. Archived from the original (PDF) on 28 September 2012. Mike McEvoy (June 12, 2008). "Hydrocodone/APAP: Drug Whys". EMS1. Archived from the original on 2012-07-10.
That said, Vanessa Rissetto, R.D., co-founder of the virtual nutrition care service Culina Health, believes the FDA's move is a positive step forward."Early-stage cancers are on the rise across ...